0.30 USD
▼-0.01-2.54%
盘后 0.41 0.00%
2026-11-20
市值
$30.71M
市盈率
—
EPS
-1.03
股息率
—
52 周区间
0.30 – 2.49
成交量
120.20K
Beta
2.49
目标价
5.00
52W 低 0.3052W 高 2.49
价格走势
公司简介
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCM...